Cue Biopharma (CUE) EBITDA (2017 - 2025)

Cue Biopharma has disclosed EBITDA across 9 years of filings, most recently posting $23.0 million for Q4 2025.

• EBITDA for Q4 2025 came in at $23.0 million, up 342.72% year-over-year; the trailing twelve-month figure through Dec 2025 was -$5.1 million (up 87.37% YoY), and the FY2025 annual result was -$5.5 million, up 86.52% from the prior year.
• EBITDA came in at $23.0 million for Q4 2025 at Cue Biopharma, up from -$7.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $23.0 million in Q4 2025 to a low of -$14.6 million in Q4 2022.
• The 5-year median for EBITDA is -$11.7 million (2022), against an average of -$9.7 million.
• Across the five-year window, EBITDA slumped 74.09% in 2022 and jumped 342.72% in 2025, its largest moves.
• Cue Biopharma's EBITDA stood at -$8.4 million in 2021, then slumped by 74.09% to -$14.6 million in 2022, then advanced by 7.96% to -$13.4 million in 2023, then advanced by 29.31% to -$9.5 million in 2024, then soared by 342.72% to $23.0 million in 2025.
• The last three EBITDA figures came in at $23.0 million (Q4 2025), -$7.4 million (Q3 2025), and -$8.5 million (Q2 2025), per Business Quant data.